In 263 patients with high-grade T1 bladder cancer and no residual tumour at second TURB, active surveillance was non-inferior to 8-dose intravesical BCG for invasive relapse-free survival (HR 0.69); any-grade adverse events 50% vs 90%.
RCTn = 263
Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial